Ansell Ltd

Healthcare AU ANN

31.77AUD
-0.41(1.27%)

Last update at 2024-11-13T05:10:00Z

Day Range

31.6131.91
LowHigh

52 Week Range

22.1532.90
LowHigh

Fundamentals

  • Previous Close 32.18
  • Market Cap4673.13M
  • Volume300146
  • P/E Ratio35.58
  • Dividend Yield1.82%
  • EBITDA242.60M
  • Revenue TTM1619.30M
  • Revenue Per Share TTM12.58
  • Gross Profit TTM 616.70M
  • Diluted EPS TTM0.90

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 189.60M 208.40M 318.10M 202.30M 143.70M
Minority interest -1.60000M -1.10000M 13.40M 11.90M 12.00M
Net income 148.30M 158.70M 246.70M 158.70M 111.70M
Selling general administrative 406.20M 429.20M 480.10M 413.00M 381.20M
Selling and marketing expenses 406.20M 429.20M 480.10M 413.00M 381.20M
Gross profit 616.70M 665.80M 810.00M 632.70M 584.00M
Reconciled depreciation 68.00M 65.30M 64.10M 55.59M 54.55M
Ebit 207.20M 226.60M 353.46M 223.10M 210.60M
Ebitda 275.20M 291.90M 401.60M 261.30M 248.80M
Depreciation and amortization 68.00M 65.30M 48.14M 38.20M 38.20M
Non operating income net other - - - - -
Operating income 316.04M 367.31M 439.95M 314.00M 210.60M
Other operating expenses 942.13M 1223.75M 989.26M 814.48M 1334.40M
Interest expense 17.60M 18.20M 19.40M 20.80M 21.40M
Tax provision 39.70M 48.60M 69.80M 42.20M 30.60M
Interest income 17.70M 24.50M 1.20M 14.50M 11.10M
Net interest income -19.40000M -19.70000M -18.20000M -30.30745M -19.39256M
Extraordinary items - - - - 0.00000M
Non recurring - - - - -
Other items - - - - -
Income tax expense 39.70M 48.60M 69.80M 42.20M 30.60M
Total revenue 1655.10M 1952.10M 2026.90M 1613.70M 1499.00M
Total operating expenses 474.20M 494.50M 544.20M 451.20M 419.40M
Cost of revenue 1038.40M 1286.30M 1216.90M 981.00M 915.00M
Total other income expense net -1.50000M -8.50000M 8.10M -25.21260M -66.90000M
Discontinued operations - - - - -
Net income from continuing ops 149.90M 159.80M 248.30M 233.28M 161.27M
Net income applicable to common shares 148.30M 158.70M 246.70M 158.70M 111.70M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 3242.60M 2530.60M 2506.20M 2737.70M 2448.60M
Intangible assets 212.50M 214.40M 1049.40M 225.70M 231.20M
Earning assets - - - - -
Other current assets 37.40M 31.10M 38.10M 37.40M 25.10M
Total liab 1332.40M 915.20M 949.60M 1173.10M 1045.20M
Total stockholder equity 1894.90M 1600.90M 1542.90M 1551.20M 1391.50M
Deferred long term liab - - - - -
Other current liab 120.40M 367.69M 185.83M 256.72M 272.85M
Common stock 1028.20M 750.70M 743.80M 769.00M 806.00M
Capital stock 1028.20M 750.70M 743.80M 769.00M 806.00M
Retained earnings 1059.80M 1026.60M 942.00M 866.80M 705.70M
Other liab - 123.60M 121.70M 128.50M 127.60M
Good will 842.30M 845.30M 834.40M 851.40M 834.70M
Other assets - 114.10M 95.80M 114.70M 101.00M
Cash 912.30M 159.40M 206.20M 240.20M 408.90M
Cash and equivalents - - - - -
Total current liabilities 423.40M 414.60M 360.30M 549.90M 408.40M
Current deferred revenue - -289.89286M -120.02972M -85.01800M -152.84670M
Net debt -55.10000M 334.90M 279.60M 275.30M 168.60M
Short term debt 77.50M 117.30M 18.20M 20.80M 68.30M
Short long term debt 59.70M 100.00M - - 72.85M
Short long term debt total 857.20M 494.30M 485.80M 515.50M 577.50M
Other stockholder equity - -2668.43822M -2441.71272M -2181.50288M -2179.44090M
Property plant equipment - 436.80M 356.60M 356.00M 307.00M
Total current assets 1623.90M 912.00M 984.50M 1166.90M 961.00M
Long term investments 5.60M 6.50M 18.00M 21.90M 17.34M
Net tangible assets - 541.20M 493.50M 474.10M 325.60M
Short term investments - 11.82M 10.82M 8.77M 7.95M
Net receivables 211.90M 191.20M 201.70M 274.20M 181.20M
Long term debt 706.60M 307.00M 426.30M 451.70M 469.90M
Inventory 457.90M 526.10M 521.30M 611.20M 340.10M
Accounts payable 225.50M 219.50M 276.30M 357.40M 220.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -193.10000M -176.40000M -142.90000M -84.60000M -120.20000M
Additional paid in capital - - - - -
Common stock total equity - - - - 1174.41M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 42.60M 42.00M 32.60M 32.70M 34.30M
Deferred long term asset charges - - - - -
Non current assets total 1618.70M 1618.60M 1521.70M 1570.80M 1487.60M
Capital lease obligations 90.90M 87.30M 59.50M 63.80M 83.93M
Long term debt total - 377.00M 467.60M 494.70M 509.20M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -75.50000M -5.10000M -1.70000M -11.90000M -11.90000M
Change to liabilities -78.90000M -94.70000M 124.20M 36.60M 5.00M
Total cashflows from investing activities -75.50000M -71.20000M -84.70000M -74.80000M -123.70000M
Net borrowings -59.50000M -17.10000M -112.10000M -37.90000M -37.90000M
Total cash from financing activities -149.20000M -176.70000M -267.50000M -198.30000M -253.40000M
Change to operating activities 0.70M -48.90000M 16.10M 6.80M 4.40M
Net income 222.66M 229.86M 329.00M 226.91M 111.70M
Change in cash -46.80000M -34.00000M -168.70000M 11.40M -192.30000M
Begin period cash flow 206.20M 240.20M 408.90M 397.50M 589.80M
End period cash flow 159.40M 206.20M 240.20M 408.90M 397.50M
Total cash from operating activities 271.00M 321.54M 230.45M 415.43M 188.90M
Issuance of capital stock 0.30M 103.20M - - -
Depreciation 96.99M 87.19M 76.55M 73.46M 38.20M
Other cashflows from investing activities -8.30000M -3.70000M -2.00000M -10.00000M -4.70000M
Dividends paid 62.90M 86.80M 77.30M 61.80M 60.20M
Change to inventory 13.21M 98.35M -347.40280M -20.28600M 2.40M
Change to account receivables 22.22M 85.60M -107.88824M 17.53M 3.50M
Sale purchase of stock -8.00000M -48.50000M -58.00000M -67.90000M -181.10000M
Other cashflows from financing activities -19.20000M -45.80000M -20.80000M -198.65790M -12.10000M
Change to netincome 15.10M 32.90M 46.70M 29.50M 31.60M
Capital expenditures 67.30M 72.60M 82.70M 64.80M 48.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 35.43M 183.95M -455.29104M -2.75310M -
Stock based compensation -8.25770M -3.76584M 40.14M 14.92M -
Other non cash items -48.64536M 4.49M -175.10168M 115.05M -149.90000M
Free cash flow 203.70M 248.94M 147.75M 350.63M 140.90M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ANN
Ansell Ltd
-0.41 1.27% 31.77 35.58 21.01 2.85 1.58 1.82 14.56
RMD
Resmed Inc DRC
-0.55 1.44% 37.60 32.17 24.81 11.30 7.04 7.59 22.46
FPH
Fisher & Paykel Healthcare Corporation Limited
-0.26 0.76% 33.95 166.10 51.81 11.13 12.06 12.02 57.37
NAN
Nanosonics Ltd
-0.02 0.60% 3.30 81.00 65.79 5.78 5.33 4.96 39.15
TRJ
Trajan Group Holdings Ltd
0.03 2.65% 1.16 - 20.00 1.18 1.78 1.47 21.80

Reports Covered

Stock Research & News

Profile

Ansell Limited designs, sources, develops, manufactures, distributes, and sells hand and body protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates in two segments, Healthcare and Industrial. The Healthcare segment manufactures and markets solutions comprising surgical gloves, single use and examination gloves, and clean and sterile gloves and garments, as well as consumables for hospitals, surgical centers, dental surgeries, veterinary clinics, first responders, manufacturers, auto repair shops, chemical plants, laboratories, and life sciences and pharmaceutical companies. The Industrial segment manufactures and markets hand and chemical protective clothing solutions for a range of industrial applications, including automotive, chemical, metal fabrication, machinery and equipment, food, construction, mining, oil and gas, utilities, logistics, and first responders. The company was formerly known as Pacific Dunlop Limited and changed its name to Ansell Limited in 2002. Ansell Limited was founded in 1893 and is based in Richmond, Australia.

Ansell Ltd

678 Victoria Street, Richmond, VIC, Australia, 3121

Key Executives

Name Title Year Born
Mr. Neil I. Salmon ACMA, BA MD, CEO & Director 1969
Mr. Zubair Javeed Chief Financial Officer NA
Mr. Darryl Nazareth Pres of Healthcare GBU NA
Mr. Rikard Fröberg MA, MS Pres of the Industrial Global Bus. Unit (IGBU) NA
Mr. John Marsden Sr. VP of Global Operations & Global Supply Chain NA
Ms. Deanna Johnston Sr. VP & Global Chief Information Officer NA
Michael Evans Director of Corp. Devel. & Investor Relation NA
Mr. Michael Gilleece Sr. VP & Corp. Gen. Counsel NA
Ms. Amanda Manzoni Chief HR Officer NA
Mr. Francois Le Jeune BS, MBA, MS Chief Commercial Officer of EMEA, APAC & Guardian Admin. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.